In NSCLC, the only predictive biomarker in clinical routine practice is PD‐L1 expression where expression on tumour cells and sometimes including immune cells is quantified to obtain a percentage of PD‐L1 positivity that is used to make treatment decisions. The gene discussed is CD274; the disease is neoplasm.